ATE325866T1 - Verwendung von l-alpha lipophosphatidylcholine zur in vitro differenzierung von monocyten in reifen dendritische zellen - Google Patents

Verwendung von l-alpha lipophosphatidylcholine zur in vitro differenzierung von monocyten in reifen dendritische zellen

Info

Publication number
ATE325866T1
ATE325866T1 AT03725275T AT03725275T ATE325866T1 AT E325866 T1 ATE325866 T1 AT E325866T1 AT 03725275 T AT03725275 T AT 03725275T AT 03725275 T AT03725275 T AT 03725275T AT E325866 T1 ATE325866 T1 AT E325866T1
Authority
AT
Austria
Prior art keywords
dendritic cells
monocytes
agent
alpha
lymphocytes
Prior art date
Application number
AT03725275T
Other languages
English (en)
Inventor
Vincent Lotteau
Patrice Andre
Original Assignee
Biomerieux Sa
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0203499A external-priority patent/FR2836828A1/fr
Application filed by Biomerieux Sa, Inst Nat Sante Rech Med filed Critical Biomerieux Sa
Application granted granted Critical
Publication of ATE325866T1 publication Critical patent/ATE325866T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT03725275T 2002-03-11 2003-03-07 Verwendung von l-alpha lipophosphatidylcholine zur in vitro differenzierung von monocyten in reifen dendritische zellen ATE325866T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0203499A FR2836828A1 (fr) 2002-03-11 2002-03-11 Utilisation de l-alpha-lysophosphatidylcholine pour obtenir la differenciation de monocytes en cellules dendritiques matures in vitro
FR0301063A FR2836829B1 (fr) 2002-03-11 2003-01-30 Utilisation de l-alpha-lysophosphatidylcholine pour obtenir la differenciation de monocytes en cellules dendritiques matures in vitro

Publications (1)

Publication Number Publication Date
ATE325866T1 true ATE325866T1 (de) 2006-06-15

Family

ID=27767084

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03725275T ATE325866T1 (de) 2002-03-11 2003-03-07 Verwendung von l-alpha lipophosphatidylcholine zur in vitro differenzierung von monocyten in reifen dendritische zellen

Country Status (9)

Country Link
US (3) US7368287B2 (de)
EP (2) EP1666039A1 (de)
JP (1) JP4482683B2 (de)
AT (1) ATE325866T1 (de)
AU (1) AU2003227822A1 (de)
DE (1) DE60305167T2 (de)
ES (1) ES2262994T3 (de)
FR (1) FR2836829B1 (de)
WO (1) WO2003076602A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101951933B1 (ko) * 2013-03-12 2019-02-25 주식회사 아리바이오 라이소포스파티딜콜린 또는 이의 유도체를 포함하는 지질나노물질 및 이의 제조방법
JP6692748B2 (ja) * 2013-09-26 2020-05-13 ナショナル ユニヴァーシティー オブ シンガポール リゾホスファチジルコリンの足場を利用する組成物及び方法
EP3000471A1 (de) * 2014-09-28 2016-03-30 Bernhard-Nocht-Institut für Tropenmedizin Neue immunstimulierende Moleküle
EP3357512A4 (de) 2015-09-29 2019-05-29 Osaka University Promoter der leukozyteninfiltration und tumorimmunaktivator
KR101862502B1 (ko) * 2017-01-02 2018-05-29 성균관대학교산학협력단 재구성 인공 암세포, 이의 제조 방법, 및 이를 포함하는 항암 조성물
WO2025221606A1 (en) * 2024-04-16 2025-10-23 Corner Therapeutics, Inc. Lipids for hyperactivation of mammalian dendritic cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4874795A (en) * 1985-04-02 1989-10-17 Yesair David W Composition for delivery of orally administered drugs and other substances
US4746652A (en) * 1986-11-18 1988-05-24 Wake Forest University Method of inducing diuresis with lysophospholipids
US5434182A (en) * 1987-12-31 1995-07-18 Isaacs; Charles E. Antibacterial fatty acid compositions
CA2090738C (en) * 1993-02-24 1996-05-21 Hema-Quebec Use of paf
US5594015A (en) * 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
US5925657A (en) * 1997-06-18 1999-07-20 The General Hospital Corporation Use of PPARγ agonists for inhibition of inflammatory cytokine production
US6191154B1 (en) * 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
GB0024361D0 (en) * 2000-10-05 2000-11-22 Glaxo Group Ltd Medicaments
FR2826975B1 (fr) * 2001-07-09 2004-06-04 Bio Merieux Utilisation de lipoproteines oxydees pour obtenir la differenciation de monocytes en cellules dendritiques matures

Also Published As

Publication number Publication date
EP1483374B1 (de) 2006-05-10
FR2836829B1 (fr) 2005-11-25
WO2003076602A3 (fr) 2004-04-08
AU2003227822A1 (en) 2003-09-22
JP2005530488A (ja) 2005-10-13
ES2262994T3 (es) 2006-12-01
DE60305167D1 (de) 2006-06-14
US20050054095A1 (en) 2005-03-10
DE60305167T2 (de) 2007-05-31
US20080176820A1 (en) 2008-07-24
EP1666039A1 (de) 2006-06-07
US7368287B2 (en) 2008-05-06
AU2003227822A8 (en) 2003-09-22
US20110135684A1 (en) 2011-06-09
WO2003076602A2 (fr) 2003-09-18
FR2836829A1 (fr) 2003-09-12
EP1483374A2 (de) 2004-12-08
JP4482683B2 (ja) 2010-06-16

Similar Documents

Publication Publication Date Title
Zou et al. Effects of short-chain fatty acids in inhibiting HDAC and activating p38 MAPK are critical for promoting B10 cell generation and function
Soberanes et al. Metformin targets mitochondrial electron transport to reduce air-pollution-induced thrombosis
Neumann et al. Production of a macrophage growth factor (s) by a goldfish macrophage cell line and macrophages derived from goldfish kidney leukocytes
Broadhurst et al. Upregulation of retinal dehydrogenase 2 in alternatively activated macrophages during retinoid-dependent type-2 immunity to helminth infection in mice
Morgun et al. Epidermal stem cells in hair follicle cycling and skin regeneration: a view from the perspective of inflammation
Granick et al. Staphylococcus aureus recognition by hematopoietic stem and progenitor cells via TLR2/MyD88/PGE2 stimulates granulopoiesis in wounds
Kavian et al. Arsenic trioxide prevents murine sclerodermatous graft-versus-host disease
Chen et al. Follicular helper T cells promote liver pathology in mice during Schistosoma japonicum infection
Rani et al. Burn wound γδ T-cells support a Th2 and Th17 immune response
Brain et al. Biologic potential of pulmonary macrophages
Ryans et al. The immunoregulatory role of alpha enolase in dendritic cell function during Chlamydia infection
Kim et al. Vitamin A metabolism by dendritic cells triggers an antimicrobial response against Mycobacterium tuberculosis
Matsui et al. Lipoteichoic acid from Staphylococcus aureus induces Th2‐prone dermatitis in mice sensitized percutaneously with an allergen
Salaiza‐Suazo et al. Treatment of two patients with diffuse cutaneous leishmaniasis caused by Leishmania mexicana modifies the immunohistological profile but not the disease outcome
Dai et al. Contributions of immune cells and stromal cells to the pathogenesis of systemic sclerosis: recent insights
ATE325866T1 (de) Verwendung von l-alpha lipophosphatidylcholine zur in vitro differenzierung von monocyten in reifen dendritische zellen
Monasterio et al. Immunostimulatory activity of low-molecular-weight hyaluronan on dendritic cells stimulated with Aggregatibacter actinomycetemcomitans or Porphyromonas gingivalis
Setúbal et al. Human neutrophils functionality under effect of an Asp49 phospholipase A2 isolated from Bothrops atrox venom
Lad et al. Glioblastoma induces the recruitment and differentiation of hybrid neutrophils from skull bone marrow
Lei et al. Elevated frequencies of CD 4+ IL‐21+ T, CD 4+ IL‐21R+ T and IL‐21+ Th17 cells, and increased levels of IL‐21 in bleomycin‐induced mice may be associated with dermal and pulmonary inflammation and fibrosis
O'Neal et al. Bhlhe40 limits early IL-10 production from CD4+ T cells during Plasmodium yoelii 17X infection
CN108883131B (zh) 调节髓源性抑制细胞的炎性小体活化用于治疗GvHD或肿瘤
Wu et al. Single-cell analysis of graft-infiltrating host cells identifies caspase-1 as a potential therapeutic target for heart transplant rejection
de Vries et al. The enigmatic role of mast cells in dominant tolerance
Matsui et al. Topical application of josamycin inhibits development of atopic dermatitis-like skin lesions in NC/Nga mice

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties